Sara Montemuiño1, Núria Rodriguez de Dios2,3, Margarita Martín4, Begoña Taboada5, Patricia Calvo-Crespo5, María Pilar Samper-Ots6, José Luis López-Guerra7, M López-Mata8, Josep Jové-Teixidó9, Verónica Díaz-Díaz10, Lourdes de Ingunza-Barón10, Mauricio Murcia-Mejía11, Marisa Chust12, Tamara García-Cañibano1, María Luz Couselo13, María Mar Puertas14, Elia Del Cerro15,16, Javier Moradiellos17, Sergio Amor17, A Varela17, I J Thuissard18, David Sanz-Rosa18, Felipe Couñago15,16. 1. Department of Radiation Oncology, Hospital Universitario de Fuenlabrada, Camino del Molino, 2, 28942, Fuenlabrada, Madrid, Spain. 2. Department of Radiation Oncology, Hospital del Mar, Passeig Marítim, 25-29, 08003 Barcelona, Spain. 3. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 4. Department of Radiation Oncology, Hospital Universitario Ramon y Cajal, Carretera de Colmenar Viejo Km9, Madrid, Spain. 5. Department of Radiation Oncology, Complexo Hospitalario Universitario Santiago de Compostela, Choupana s/n, bloque d. Santiago de Compostela, A Coruña, Spain. 6. Department of Radiation Oncology, Hospital Universitario Rey Juan Carlos, C/ Gladiolo s/n. Móstoles, Madrid, Spain. 7. Department of Radiation Oncology, Hospital Universitario Virgen del Rocio, Av. Manuel Siurot, S/N, 41013 Sevilla, Spain. 8. Department of Radiation Oncology, Hospital Clinico Universitario Lozano Blesa, San Juan Bosco 15, Zaragoza, Spain. 9. Department of Radiation Oncology, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, 08916, Badalona, Spain. 10. Department of Radiation Oncology, Hospital Universitario Puerta del Mar, Av. Ana de Viya, 21, 11009, Cadiz, Spain. 11. Department of Radiation Oncology, Hospital Universitari Sant Joan de Reus, Av. del Dr. Josep Laporte, 2, 43204 Reus, Tarragona, Spain. 12. Department of Radiation Oncology, Instituto Valenciano de Oncologia, Carrer del Professor Beltrán Báguena, 8, 46009, Valencia, Spain. 13. Department of Radiation Oncology, Hospital Central de la Defensa Gomez Ulla, Glorieta Ejército, 1, 28047, Madrid, Spain. 14. Department of Radiation Oncology, Hospital Universitario Miguel Servet, Paseo Isabel la Católica, 1-3, 50009, Zaragoza, Spain. 15. Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, C/ Diego de Velázquez, 1, 28223, Pozuelo de Alarcón, Madrid, Spain. 16. Universidad Europea de Madrid, Calle Tajo, s/n, 28670 Villaviciosa de Odón, Madrid, Spain. 17. Department of Thoracic Surgery, Hospital Universitario Quirónsalud Madrid, C/ Diego de Velázquez, 1, 28223, Pozuelo de Alarcón, Madrid, Spain. 18. School of Doctoral Studies & Research, Universidad Europea, Calle Tajo, s/n, 28670 Villaviciosa de Odón, Madrid, Spain.
Abstract
BACKGROUND: The optimal induction treatment in potentially-resectable stage IIIA-N2 NSCLC remains undefined. AIM: To compare neoadjuvant high-dose chemoradiotherapy (CRT) to neoadjuvant chemotherapy (CHT) in patients with resectable, stage IIIA-N2 non-small-cell lung cancer (NSCLC). METHODS: Retrospective, multicentre study of 99 patients diagnosed with stage cT1-T3N2M0 NSCLC who underwent neoadjuvant treatment (high-dose CRT or CHT) followed by surgery between January 2005 and December 2014. RESULTS: 47 patients (47.5%) underwent CRT and 52 (52.5%) CHT, with a median follow-up of 41 months. Surgery consisted of lobectomy (87.2% and 82.7%, in the CRT and CHT groups, respectively) or pneumonectomy (12.8% vs. 17.3%). Nodal downstaging (to N1/N0) and Pathologic complete response (pCR; pT0pN0) rates were significantly higher in the CRT group (89.4% vs. 57.7% and 46.8% vs. 7.7%, respectively; p < 0.001)). Locoregional recurrence was significantly lower in the CRT group (8.5% vs. 13.5%; p = 0.047) but distant recurrence rates were similar in the two groups. Median PFS was 45 months (CHT) vs. "not reached" (CRT). Median OS was similar: 61 vs. 56 months (p = 0.803). No differences in grade ≥3 toxicity were observed. On the Cox regression analysis, advanced pT stage was associated with worse OS and PFS (p < 0.001) and persistent N2 disease (p = 0.002) was associated with worse PFS. CONCLUSIONS: Compared to neoadjuvant chemotherapy alone, a higher proportion of patients treated with preoperative CRT achieved nodal downstaging and pCR with better locoregional control. However, there were no differences in survival. More studies are needed to know the optimal treatment of these patients.
BACKGROUND: The optimal induction treatment in potentially-resectable stage IIIA-N2 NSCLC remains undefined. AIM: To compare neoadjuvant high-dose chemoradiotherapy (CRT) to neoadjuvant chemotherapy (CHT) in patients with resectable, stage IIIA-N2 non-small-cell lung cancer (NSCLC). METHODS: Retrospective, multicentre study of 99 patients diagnosed with stage cT1-T3N2M0 NSCLC who underwent neoadjuvant treatment (high-dose CRT or CHT) followed by surgery between January 2005 and December 2014. RESULTS: 47 patients (47.5%) underwent CRT and 52 (52.5%) CHT, with a median follow-up of 41 months. Surgery consisted of lobectomy (87.2% and 82.7%, in the CRT and CHT groups, respectively) or pneumonectomy (12.8% vs. 17.3%). Nodal downstaging (to N1/N0) and Pathologic complete response (pCR; pT0pN0) rates were significantly higher in the CRT group (89.4% vs. 57.7% and 46.8% vs. 7.7%, respectively; p < 0.001)). Locoregional recurrence was significantly lower in the CRT group (8.5% vs. 13.5%; p = 0.047) but distant recurrence rates were similar in the two groups. Median PFS was 45 months (CHT) vs. "not reached" (CRT). Median OS was similar: 61 vs. 56 months (p = 0.803). No differences in grade ≥3 toxicity were observed. On the Cox regression analysis, advanced pT stage was associated with worse OS and PFS (p < 0.001) and persistent N2 disease (p = 0.002) was associated with worse PFS. CONCLUSIONS: Compared to neoadjuvant chemotherapy alone, a higher proportion of patients treated with preoperative CRT achieved nodal downstaging and pCR with better locoregional control. However, there were no differences in survival. More studies are needed to know the optimal treatment of these patients.
Authors: Michael Thomas; Christian Rübe; Petra Hoffknecht; Hans N Macha; Lutz Freitag; Albert Linder; Norman Willich; Michael Hamm; Gerhard W Sybrecht; Dieter Ukena; Karl-Matthias Deppermann; Cornelia Dröge; Dorothea Riesenbeck; Achim Heinecke; Cristina Sauerland; Klaus Junker; Wolfgang E Berdel; Michael Semik Journal: Lancet Oncol Date: 2008-06-24 Impact factor: 41.316
Authors: Martin Früh; Daniel C Betticher; Roger Stupp; Alexandros Xyrafas; Solange Peters; Hans Beat Ris; Rene Olivier Mirimanoff; Adrian F Ochsenbein; Ralph Schmid; Oscar Matzinger; Rolf A Stahel; Walter Weder; Matthias Guckenberger; Sacha I Rothschild; Didier Lardinois; Nicholas Mach; Michael Mark; Oliver Gautschi; Sandra Thierstein; Christine Biaggi Rudolf; Miklos Pless Journal: J Thorac Oncol Date: 2018-09-26 Impact factor: 15.609
Authors: Junghee Lee; Hong Kwan Kim; Byung Jo Park; Jong Ho Cho; Yong Soo Choi; Jae Ill Zo; Young Mog Shim; Hongryull Pyo; Yong Chan Ahn; Jin Seok Ahn; Myung-Ju Ahn; Keunchil Park; Jhingook Kim Journal: Lung Cancer Date: 2017-11-22 Impact factor: 5.705
Authors: Asad A Shah; Mark F Berry; Ching Tzao; Mihir Gandhi; Mathias Worni; Ricardo Pietrobon; Thomas A D'Amico Journal: Ann Thorac Surg Date: 2012-06 Impact factor: 4.330
Authors: Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox Journal: Lancet Date: 2009-07-24 Impact factor: 79.321
Authors: Seth B Krantz; Brian Mitzman; Waseem Lutfi; Kristine Kuchta; Chi-Hsiung Wang; John A Howington; Ki Wan Kim Journal: Ann Thorac Surg Date: 2018-02-14 Impact factor: 4.330
Authors: Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu Journal: N Engl J Med Date: 2017-09-08 Impact factor: 91.245
Authors: K S Albain; V W Rusch; J J Crowley; T W Rice; A T Turrisi; J K Weick; V A Lonchyna; C A Presant; R J McKenna; D R Gandara Journal: J Clin Oncol Date: 1995-08 Impact factor: 44.544